Jeena Sikho Lifecare Limited has received the National Accreditation Board for Hospitals & Healthcare Providers (NABH) Certificate of Accreditation for its Sanganer Hospital, marking a significant milestone in the company's commitment to quality healthcare delivery. The company announced this development on January 1, 2026, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Accreditation Details

The NABH accreditation specifically covers Panchakarma services at the Sanganer Hospital located in Rajasthan. The certification demonstrates the facility's compliance with nationally recognized healthcare standards.

Significance of NABH Accreditation

The receipt of NABH accreditation represents adherence to nationally recognized standards across multiple critical areas of healthcare operations. This certification validates the hospital's commitment to quality healthcare delivery, patient safety protocols, and operational excellence. The accreditation process involves rigorous evaluation of healthcare facilities against established benchmarks.

Business Impact

The company has indicated that this development has occurred in the ordinary course of business. The NABH accreditation enhances the credibility and recognition of Jeena Sikho Lifecare Limited's healthcare services, particularly in the specialized area of Panchakarma treatments at its Rajasthan facility.

Regulatory Compliance

The announcement was made in compliance with regulatory disclosure requirements under SEBI regulations. Additional information regarding this development is available on the company's investor relations website at https://jeenasikho.com/investors , ensuring transparency for stakeholders and investors.

Jeena Sikho Lifecare Limited has announced the grant of 2,18,875 employee stock options to 1,176 eligible employees under its ESOP 2025 scheme. The Nomination and Remuneration Committee of the Board of Directors approved this grant on January 1, 2026, marking a significant step in the company's employee incentivization strategy aimed at employee motivation and long-term value creation.

ESOP Grant Details

The comprehensive employee stock option grant encompasses substantial participation across the organization. The scheme demonstrates the company's commitment to employee motivation and long-term value creation through equity participation.

Regulatory Compliance and Structure

The ESOP 2025 scheme operates in full compliance with SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021, and other applicable laws. Each stock option, upon exercise, will convert into one fully paid-up equity share of face value ₹2.00 each, providing employees with direct ownership stakes in the company.

The exercise period will commence from the date of vesting and expire upon completion of one year from the vesting date. This structure provides employees with a defined timeframe to exercise their options while maintaining alignment with company performance objectives.

Share Rights and Benefits

Shares arising from the conversion of these options will rank pari passu with all other existing equity shares of the company. This ensures that employees exercising their options receive full shareholder rights and benefits equivalent to other equity holders.

The grant represents a strategic initiative to retain talent and align employee interests with long-term company growth. The substantial number of beneficiaries across 1,176 employees indicates broad-based participation in the company's equity growth potential.

Implementation Timeline and Disclosure

The formal disclosure was made pursuant to Regulation 30 of SEBI Listing Regulations read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024. The company has fulfilled all regulatory requirements for the grant announcement, with Managing Director Manish Grover signing the official communication from the company's Zirakpur, Punjab location.

This ESOP grant establishes a foundation for employee engagement through equity participation while maintaining compliance with all applicable securities regulations and disclosure requirements.